| Hepatoprotective and anti-inflammatory cytokines in alcoholic liver disease. | |
| | |
MedLine Citation:
|
PMID: 22320924 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The activation of innate immunity by various factors (e.g. lipopolysaccharide and complements) plays an important role in initiating and promoting alcoholic liver injury via the stimulation of Kupffer cells to induce oxidative stress and to produce pro-inflammatory cytokines (e.g. tumor necrosis factor [TNF]-α) that cause hepatocellular damage. Accumulating evidence suggests that the activation of innate immunity also stimulates Kupffer cells to produce the hepatoprotective cytokine interleukin-6 (IL-6) and the anti-inflammatory cytokine IL-10 during alcoholic liver injury. IL-6 protects against alcoholic liver injury via the activation of signal transducer and activator of transcription 3 (STAT3) and the subsequent induction of a variety of hepatoprotective genes in hepatocytes. IL-10 inhibits alcoholic liver inflammation via the activation of STAT3 in Kupffer cells/macrophages and the subsequent inhibition of liver inflammation. Recent studies have suggested that IL-10 may play a dual role in controlling ethanol-induced steatosis and liver injury via the inhibition of the pro-inflammatory cytokine TNF-α, thereby ameliorating alcoholic liver injury, or via the inhibition of the hepatoprotective cytokine IL-6, thereby potentiating alcoholic liver injury. IL-22 is another important hepatoprotective cytokine that protects against acute and chronic alcoholic liver injury by binding to a receptor complex composed of IL-10R2 and IL-22R chains on the surfaces of hepatocytes. Finally, IL-22 treatment is a potential therapeutic option for treating severe forms of alcoholic liver disease because of its antioxidant, antiapoptotic, antisteatotic, proliferative, and antimicrobial effects, as well as the potential added benefit of few side effects. |
| | |
Authors:
|
Bin Gao |
Related Documents
:
|
23164664 - 2,3,7,8-tcdd enhances the sensitivity of mice to concanavalin a immune-mediated liver i... 18060474 - Induction of apoptosis by hydrogen peroxide in hpv 16 positive human cervical cancer ce... |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Intramural; Review |
Journal Detail:
|
Title: Journal of gastroenterology and hepatology Volume: 27 Suppl 2 ISSN: 1440-1746 ISO Abbreviation: J. Gastroenterol. Hepatol. Publication Date: 2012 Mar |
Date Detail:
|
Created Date: 2012-02-10 Completed Date: 2012-06-06 Revised Date: 2013-05-20 |
Medline Journal Info:
|
Nlm Unique ID: 8607909 Medline TA: J Gastroenterol Hepatol Country: Australia |
Other Details:
|
Languages: eng Pagination: 89-93 Citation Subset: IM |
Copyright Information:
|
Published © 2012 This article is a U.S. Government work and is in the public domain in the USA. |
Affiliation:
|
Laboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland 20892, USA. bgao@mail.nih.gov |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Anti-Inflammatory Agents / therapeutic use* Cytokines / metabolism, therapeutic use* Cytoprotection Humans Immunity, Innate / drug effects Inflammation Mediators / metabolism Interleukin-10 / metabolism Interleukin-6 / metabolism Interleukins / metabolism, therapeutic use Kupffer Cells / drug effects, immunology Liver / drug effects*, immunology, pathology Liver Diseases, Alcoholic / drug therapy*, immunology, pathology STAT3 Transcription Factor / metabolism Treatment Outcome |
| Grant Support | |
ID/Acronym/Agency:
|
Z99 AA999999/AA/NIAAA NIH HHS; ZIA AA000369-10/AA/NIAAA NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Inflammatory Agents; 0/Cytokines; 0/Inflammation Mediators; 0/Interleukin-6; 0/Interleukins; 0/STAT3 Transcription Factor; 0/interleukin-22; 130068-27-8/Interleukin-10 |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Novel anti-fibrotic modalities for liver fibrosis: Molecular targeting and regenerative medicine in ...
Next Document: Morphogens and hepatic stellate cell fate regulation in chronic liver disease.